Patents by Inventor Robert B. Perni
Robert B. Perni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120282219Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: July 3, 2012Publication date: November 8, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: ROBERT EDWARD BABINE, SHU HUI CHEN, IVAN COLLADO, CRISTINA GARCIA-PAREDES, JOHN IRVIN GLASS, DEQI GUO, LING JIN, JASON ERIC LAMAR, RAYMOND SAMUEL PARKER, III, NANCY JUNE SNYDER, XICHENG DAVID SUN, MARK JOSEPH TEBBE, FRANTZ VICTOR, Q. MAY WANG, YVONNE YEE MAI YIP, ROBERT B. PERNI, LUC FARMER
-
Publication number: 20120270318Abstract: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.Type: ApplicationFiled: June 29, 2012Publication date: October 25, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: ESTHER MARTINBOROUGH, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul K. Bandarage, Francois Maltais, Guy Bemis
-
Publication number: 20120252780Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: October 29, 2010Publication date: October 4, 2012Inventors: Pui Yee Ng, Charles Blum, Lauren McPherson, Robert B. Perni, Chi B. Vu, Mohammed Mahmood Ahmed, Jeremy S. Disch
-
Patent number: 8268862Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: GrantFiled: January 24, 2011Date of Patent: September 18, 2012Assignee: Sirtris Pharmaceuticals, Inc.Inventors: Jean Bemis, Jeremy S. Disch, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Chi B. Vu
-
Patent number: 8247532Abstract: This invention relates to processes and intermediates for the preparation of salts of deuterated, enantiomericallv enriched alpha-amino beta-hydroxy acids of Formula 1 wherein the variables R1,R?1 and R?2 are defined herein, and wherein the process may comprise the steps of forming a salt of a compound of Formula 1, and crystallizing said salt to give a compound of greater than 55% enantiomeric excess.Type: GrantFiled: November 24, 2010Date of Patent: August 21, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert B. Perni, Youssef Bennani, Gregor Zlokarnik, Gerald J. Tanoury, Minzhang Chen, Young Chun Jung, Raymond E. Forslund, Francois Maltais
-
Patent number: 8236815Abstract: The invention relates to ion channel modulators of formula Ia, pharmaceutical compositions thereof, and to methods of treating diseases using such compounds where activation or hyperactivity of calcium and/or sodium ion channels is implicated in the disease state.Type: GrantFiled: March 15, 2010Date of Patent: August 7, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Esther Martinborough, Nicole Zimmermann, Robert B. Perni, Michael Arnost, Upul Bandarage, Francois Maltais, Guy Bemis
-
Patent number: 8217048Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.Type: GrantFiled: June 28, 2010Date of Patent: July 10, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. van Drie
-
Patent number: 8187874Abstract: The present invention relates to drug discovery methods, particularly antiviral drug discovery methods.Type: GrantFiled: October 27, 2004Date of Patent: May 29, 2012Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert B. Perni, Cynthia Gates, John Thomson
-
Publication number: 20120064034Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: November 10, 2011Publication date: March 15, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: ROBERT EDWARD BABINE, SHU HUI CHEN, IVAN COLLADO, CRISTINA GARCIA-PAREDES, JOHN IRVIN GLASS, DEQI GUO, LING JIN, JASON ERIC LAMAR, RAYMOND SAMUEL PARKER, III, NANCY JUNE SNYDER, XICHENG DAVID SUN, YVONNE YEE MAI YIP, Q. MAY WANG, FRANTZ VICTOR, MARK JOSEPH TEBBE, ROBERT B. PERNI, LUC FARMER
-
Publication number: 20120014914Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.Type: ApplicationFiled: September 21, 2011Publication date: January 19, 2012Applicant: Vertex Pharmaceuticals IncorporatedInventors: Luc J. Farmer, Robert B. Perni, Govinda Rao Bhisetti, Keith P. Wilson
-
Publication number: 20110306612Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: September 29, 2009Publication date: December 15, 2011Applicant: Sirtris Pharmaceuticals, Inc.Inventors: Chi B. Vu, Christopher Oalmann, Robert B. Perni, Brian White
-
Publication number: 20110263564Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: October 29, 2009Publication date: October 27, 2011Applicant: Sirtris Pharmaceuticals, Inc.Inventors: Radha Narayan, Jeremy S. Disch, Robert B. Perni, Chi B. Vu
-
Publication number: 20110257174Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: September 29, 2009Publication date: October 20, 2011Applicant: Sirtris Pharmaceuticals, Inc.Inventors: Christopher Oalmann, Robert B. Perni, Chi B. Vu
-
Patent number: 8039623Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.Type: GrantFiled: March 9, 2007Date of Patent: October 18, 2011Assignee: Vertex Pharmaceuticals IncorporatedInventors: Kevin M. Cottrell, Robert B. Perni, Janos Pitlik
-
Publication number: 20110171175Abstract: This invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof wherein C* represents a diastereomeric carbon comprising a mixture of R and S isomers wherein the R isomer is greater than 50% of the mixture.Type: ApplicationFiled: March 18, 2011Publication date: July 14, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Steven Lyons, Robert B. Perni
-
Publication number: 20110152254Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: January 24, 2011Publication date: June 23, 2011Applicant: Sirtris Pharmaceuticals, Inc.Inventors: Jean Bemis, Jeremy S. Disch, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Chi B. Vu
-
Publication number: 20110124637Abstract: Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: July 2, 2009Publication date: May 26, 2011Inventors: Chi B Vu, Jeremy S. Disch, Pui Yee Ng, Charles A. Blum, Robert B. Perni
-
Publication number: 20110104115Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.Type: ApplicationFiled: June 28, 2010Publication date: May 5, 2011Applicant: VERTEX PHARMACEUTICALS INCOROPRATEDInventors: Robert B. Perni, John J. Court, Shawn D. Britt, Janos Pitlik, John H. Van Drie
-
Publication number: 20110077248Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.Type: ApplicationFiled: May 28, 2009Publication date: March 31, 2011Inventors: Chi B. Vu, Pui Yee Ng, Charles A. Blum, Robert B. Perni
-
Publication number: 20110071074Abstract: A deuterated ?-ketoamido steric specific compound of the formula wherein D denotes a deuterium atom on a steric specific carbon atom.Type: ApplicationFiled: November 24, 2010Publication date: March 24, 2011Applicant: Vertex Pharmaceuticals IncorporatedInventors: Robert B. Perni, Youssef Bennani, Gregor Zlokarnik, Gerald J. Tanoury, Minzhang Chen, Young Chun Jung, Raymond E. Forslund, Francois Maltais